abstract |
There are pharmaceutical compositions for interleukin-1 mediated disease. The pharmaceutical composition comprises interleukin-1 receptor antagonists and protein stabilizers, for example, nonionic active agent surfaces, increasing viscosities. The addition of nonionic active agent surfaces or the viscosity of such receptor antagonists stabilizes. |